Traws Pharma, Inc.
TRAW
$2.16
-$0.32-12.90%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | 4,694.74% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | 4,694.74% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | 4,694.74% | |||
| SG&A Expenses | 3.13% | -38.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.83% | -24.30% | |||
| Operating Income | -224.66% | 75.99% | |||
| Income Before Tax | -333.01% | -104.26% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -333.01% | -104.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -333.01% | -104.26% | |||
| EBIT | -224.66% | 75.99% | |||
| EBITDA | -223.72% | 76.01% | |||
| EPS Basic | -220.39% | -104.96% | |||
| Normalized Basic EPS | -185.95% | -105.09% | |||
| EPS Diluted | -212.82% | -105.26% | |||
| Normalized Diluted EPS | -185.95% | -105.28% | |||
| Average Basic Shares Outstanding | 51.50% | -16.44% | |||
| Average Diluted Shares Outstanding | 51.50% | -19.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||